Clearside Biomedical(CLSD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CLSD Clearside Biomedical

Pre-Market Trading 04-09 06:05:44 EDT

0.8191

-0.0262

-3.10%

High0.9400	Low0.8014	Vol242.45K
Open0.8875	D1 Closing0.8453	Amplitude16.40%
Mkt Cap63.19M	Tradable Cap55.10M	Total Shares77.14M
T/O201.81K	T/O Rate0.36%	Tradable Shares67.27M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"CLSD","market":"US","secType":"STK","nameCN":"Clearside Biomedical","latestPrice":0.8191,"timestamp":1744142400000,"preClose":0.8453,"halted":0,"volume":242449,"delay":0,"floatShares":67269471,"shares":77143872,"eps":-0.465453,"marketStatus":"Pre-Market Trading","change":-0.0262,"latestTime":"04-09 06:05:44 EDT","open":0.8875,"high":0.94,"low":0.8014,"amount":201806.11037480002,"amplitude":0.163965,"askPrice":1.24,"askSize":100,"bidPrice":0.7316,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.465453,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1744205400000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1464840000000,"exchange":"NASDAQ","adjPreClose":0.8191,"postHourTrading":{"tag":"盘后","latestPrice":0.86,"preClose":0.8191,"latestTime":"19:48 EDT","volume":2149,"amount":1768.3153,"timestamp":1744156125395},"volumeRatio":1.49309570298939,"impliedVol":3.5184,"impliedVolPercentile":0.98},"requestUrl":"/m/hq/s/CLSD","defaultTab":"news","newsList":[{"id":"2525892799","title":"Clearside Biomedical Price Target Maintained With a $4.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2525892799","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525892799?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 21:00","pubTimestamp":1744117200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLSD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 08, 2025 09:00 ET (13:00 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLSD"],"gpt_icon":0},{"id":"2524172094","title":"Clearside Biomedical Inc (CLSD) Q4 2024 Earnings Call Highlights: Strategic Advances and ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2524172094","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524172094?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 09:00","pubTimestamp":1743555657,"startTime":"0","endTime":"0","summary":"Cash and Cash Equivalents: Approximately $20 million as of December 31, 2024.Funding Outlook: Sufficient resources to fund planned operations into the fourth quarter of 2025.For the complete transcript of the earnings call, please refer to the full earnings call transcript.Clearside Biomedical Inc  has successfully completed over 15,000 suprachoroidal injections, showcasing the reliability and safety of their SCS Microinjector.Positive results from the ODYSSEY Phase 2b wet AMD clinical trial led to a successful end of Phase 2 meeting with the FDA, aligning on a pivotal Phase 3 program for CLS-AX.Clearside Biomedical Inc  has cash and cash equivalents totaling approximately $20 million, which may only fund operations into the fourth quarter of 2025, indicating a need for additional funding.A: Victor Chong stated that enrollment is expected to take around 12 months. The FDA does not require separate adverse event rates for different groups; the drug will be assessed","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/clearside-biomedical-inc-clsd-q4-010057693.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CLSD"],"gpt_icon":0},{"id":"2524194424","title":"Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2524194424","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524194424?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 19:05","pubTimestamp":1743505500,"startTime":"0","endTime":"0","summary":"ALPHARETTA, Ga., April  01, 2025  (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc.(Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/01/3053178/0/en/Clearside-Biomedical-to-Participate-in-a-Fireside-Chat-at-the-24th-Annual-Needham-Virtual-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4137","HCSG","CLSD","BK4007"],"gpt_icon":0},{"id":"2523108079","title":"Clearside Biomedical Price Target Maintained With a $6.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2523108079","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523108079?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 19:12","pubTimestamp":1743419520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLSD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 31, 2025 07:12 ET (11:12 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLSD"],"gpt_icon":0},{"id":"2523689464","title":"Stifel Nicolaus Sticks to Its Buy Rating for Clearside Biomedical (CLSD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2523689464","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523689464?lang=en_us&edition=full_marsco","pubTime":"2025-03-29 01:46","pubTimestamp":1743184000,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on Clearside Biomedical (CLSD – Research Report) today and set a price target of $8....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-sticks-to-its-buy-rating-for-clearside-biomedical-clsd?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-sticks-to-its-buy-rating-for-clearside-biomedical-clsd?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SF","CLSD"],"gpt_icon":0},{"id":"2522850941","title":"Clearside Biomedical Price Target Maintained With a $5.00/Share by Citizens Capital Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2522850941","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522850941?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 22:57","pubTimestamp":1743173820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLSD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 28, 2025 10:57 ET (14:57 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLSD"],"gpt_icon":0},{"id":"2522275625","title":"Clearside Biomedical Is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2522275625","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522275625?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 19:15","pubTimestamp":1743160500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLSD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 28, 2025 07:15 ET (11:15 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLSD"],"gpt_icon":0},{"id":"2522732551","title":"Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2522732551","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522732551?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 05:20","pubTimestamp":1743110403,"startTime":"0","endTime":"0","summary":"Clearside Biomedical, Inc.  came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.08 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 23.08%. A quarter ago, it was expected that this company would post a loss of $0.14 per share when it actually produced a loss of $0.10, delivering a surprise of 28.57%.Clearside Biomedical , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.31 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 13.33%. This compares to year-ago revenues of $6.35 million. The company has topped consensus revenue estimates two times over the last four quarters.Clearside Biomedical shares have added about 7.4% since the beginning of the year versus the S&P 500's decline of -2.9%.While Clearside Biomedical has outperformed the market so f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/clearside-biomedical-inc-clsd-reports-212003389.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CLSD"],"gpt_icon":0},{"id":"2522532465","title":"Clearside Biomedical Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2522532465","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522532465?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 05:02","pubTimestamp":1743109345,"startTime":"0","endTime":"0","summary":"Clearside Biomedical Inc reports results for the quarter ended December 31 - Earnings SummaryClearside Biomedical Inc CLSD.OQ reported a quarterly adjusted loss of 10 cents per share for the quarter e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nL5N3QA26X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLSD"],"gpt_icon":0},{"id":"2522321745","title":"Clearside Biomedical Reports 2024 Financial Results and Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2522321745","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522321745?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 04:51","pubTimestamp":1743108707,"startTime":"0","endTime":"0","summary":"Clearside Biomedical ( ($CLSD) ) has provided an update. On March 27, 2025, Clearside Biomedical announced its financial results for the fourth qua...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/clearside-biomedical-reports-2024-financial-results-and-updates?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/clearside-biomedical-reports-2024-financial-results-and-updates?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLSD","BK4007"],"gpt_icon":0},{"id":"2522953187","title":"Clearside Biomedical Q4 2024 GAAP EPS $(0.10), Inline, Sales $306.00K Beat $176.67K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2522953187","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522953187?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 04:17","pubTimestamp":1743106647,"startTime":"0","endTime":"0","summary":"Clearside Biomedical (NASDAQ:CLSD) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is a 25 percent decrease over losses of $(0.08) per share from the same period last year. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44524171/clearside-biomedical-q4-2024-gaap-eps-0-10-inline-sales-306-00k-beat-176-67k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLSD"],"gpt_icon":0},{"id":"2522539601","title":"Clearside Biomedical Q4 EPS USD -0.1","url":"https://stock-news.laohu8.com/highlight/detail?id=2522539601","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522539601?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 04:05","pubTimestamp":1743105901,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nPLX490202:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLSD","BK4007"],"gpt_icon":0},{"id":"2522053191","title":"Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2522053191","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522053191?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 04:05","pubTimestamp":1743105900,"startTime":"0","endTime":"0","summary":"- Successful End-of-Phase 2 Meeting with FDA Results in Alignment on Phase 3 Plans for CLS-AX in Wet AMD -. - Asia-Pacific Partner’s New Drug Application for ARCATUS  for Uveitic Macular Edema Accepted for Regulatory Review in China -. - Multiple Medical Meeting Presentations Highlight Potential Advantages and Key Differentiators of Suprachoroidal Drug Delivery Utilizing Clearside’s SCS Microinjector -. - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET -. “We are redefining the delivery of therapeutics to the retina through the suprachoroidal space with the proven reliability and broad applicability of our innovative SCS Microinjector,” said George Lasezkay, PharmD, JD, President and Chief Executive Officer. “Over the past six months, we announced positive Phase 2b data, conducted a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration , designed the CLS-AX  Phase 3 program to maximize commercial potential in wet AMD, and supported several of","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/clearside-biomedical-announces-fourth-quarter-200500116.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0198837287.USD","LU2458330243.SGD","BK4554","BK4512","BK4605","LU0823421333.USD","LU0719512351.SGD","LU1989764664.SGD","LU0889565833.HKD","LU1880398554.USD","LU0390134368.USD","LU1951198990.SGD","LU0823434740.USD","IE00BMPRXR70.SGD","BK4575","IE00BMPRXN33.USD","LU0642271901.SGD","LU1303367103.USD","GFS","BK4612","LU2264538146.SGD","LU2250418816.HKD","LU1803068979.SGD","LU2054465674.USD","LU0056508442.USD","LU0823434583.USD","LU1064131342.USD","BK4573","BK4614","BK4566","LU0082616367.USD","LU1923623000.USD","LU1242518857.USD","IE0004445239.USD","LU1242518931.SGD","LU1988902786.USD","CLSD","IE0009356076.USD","BK4007","LU0109392836.USD","LU0127658192.USD","IE00B5949003.HKD","BK4532","LU2360106780.USD","LU0081259029.USD","LU2458330169.SGD","LU1880398471.USD","BK4588","BK4585"],"gpt_icon":1},{"id":"2522329609","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2522329609","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522329609?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 18:00","pubTimestamp":1743069600,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·INmune Bio Inc.                                 4Q      (.55)  4:05 PM. ·TD SYNNEX Corp                                   1Q      2.91   8:05 AM","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FC","FBIO","LULU","CALC","WBA","PVH","SDST","DARE","TLSI","KYTX","ATAI","IKT","ADCT","PVLA","INMB","BRZE","GOVX","EDAP","RANI","SGML","BW","NUTX","FTCI","GEVO","FEMY","INR","NCNO","SKYH","SLRN","LNZA","WKSP","CLSD","GWH","PENG","WGO","MDAI","REKR","BLRX","SPWH","CELC","ANGO","PRGS","BHST","NNOX","UNCY","RLMD","AFMD","BCAB","CRDL","TSAT"],"gpt_icon":0},{"id":"2522838709","title":"Clearside Biomedical Inc  expected to post a loss of 10 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2522838709","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522838709?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 04:43","pubTimestamp":1742935398,"startTime":"0","endTime":"0","summary":"Clearside Biomedical Inc  expected to post a loss of10cents a share - Earnings Preview Clearside Biomedical Inc CLSD.OQ CLSD.O is expected to show a fall in quarterly revenue when it reports  results ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nL5N3Q822H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLSD"],"gpt_icon":0},{"id":"2521174675","title":"Clearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2521174675","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521174675?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 19:05","pubTimestamp":1742814300,"startTime":"0","endTime":"0","summary":"- Suprachoroidal Delivery Develops as Promising Mainstream Procedure for Treating Multiple Macular Diseases - - SCS Microinjector Provides Targeted and Compartmentalized Delivery of Therapeutics Direc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/24/3047721/0/en/Clearside-Biomedical-Announces-Six-Abstracts-Accepted-for-Presentation-at-Association-for-Research-in-Vision-and-Ophthalmology-ARVO-2025-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0198837287.USD","LU2458330243.SGD","LU1951200564.SGD","BK4554","BK4512","BK4605","BK4585","LU0823421333.USD","LU0719512351.SGD","LU1989764664.SGD","LU0889565833.HKD","LU1880398554.USD","LU0390134368.USD","BK4141","LU2098885051.SGD","LU1951198990.SGD","LU0823434740.USD","IE00BMPRXR70.SGD","BK4575","LU0642271901.SGD","LU1316542783.SGD","LU1303367103.USD","BK4612","LU0979878070.USD","LU2264538146.SGD","LU1803068979.SGD","LU2054465674.USD","LU0056508442.USD","BK4529","LU0823434583.USD","BK4614","BK4566","LU0082616367.USD","LU1242518857.USD","IE0004445239.USD","BK4534","LU1242518931.SGD","CLSD","IE0009356076.USD","BK4007","LU0109392836.USD","LU0127658192.USD","LU1988902786.USD","LU2360106780.USD","LU0081259029.USD","LU2458330169.SGD","LU1880398471.USD","BK4588","BK4543"],"gpt_icon":1},{"id":"2521714099","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2521714099","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521714099?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 18:00","pubTimestamp":1742810400,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Comp de San Bas                                  4Q       .36       AMC. ·Oklo Inc. Class A                               4Q      (.07)      AMC. ·Core & Main Inc.                                 4Q       .36       BMO. ·McCormick & Co                                 1Q       .64   6:30 AM","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANTX","EDAP","OBIO","IKT","CDLR","FBIO","MKC","GRDN","PAYX","ZURA","TEN","UNCY","RVPH","SURG","WBA","THRD","CLSD","ALUR","DERM","MLKN","PAYS","ABL","NUTX","CRMD","CALC","IOBT","KOD","IVA","MREO","XFOR","CHWY","CTAS","SCS","BCAB","DLTR","KBH","AFMD","MDAI","BEEM","WGO","GOVX","RLMD","LPTX","WOOF","SDST","PDSB","SKYX","CNXC","SLRN","ACRV"],"gpt_icon":0},{"id":"2521068469","title":"Positive Outlook for Clearside Biomedical’s CLS-AX in Wet AMD Market with Competitive Trial Results and Flexible Dosing Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2521068469","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521068469?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 00:15","pubTimestamp":1742487317,"startTime":"0","endTime":"0","summary":"JMP Securities analyst Jonathan Wolleben has reiterated their bullish stance on CLSD stock, giving a Buy rating on March 6. Jonathan Wolleben has g...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/positive-outlook-for-clearside-biomedicals-cls-ax-in-wet-amd-market-with-competitive-trial-results-and-flexible-dosing-strategy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/positive-outlook-for-clearside-biomedicals-cls-ax-in-wet-amd-market-with-competitive-trial-results-and-flexible-dosing-strategy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0823434583.USD","LU0889565833.HKD","LU1242518857.USD","LU2458330243.SGD","BK4595","LU1803068979.SGD","BK4023","LU1951200564.SGD","LU1064131342.USD","BK4585","LU0109392836.USD","BK4007","LU0823421416.USD","LU1316542783.SGD","BK4145","CLS","BK4534","BK4211","LU1951198990.SGD","IE0009356076.USD","LU2264538146.SGD","BK4605","CLSD","BK4554","LU1242518931.SGD","LU2125910500.SGD","LU1852331112.SGD","LU0198837287.USD","LU0081259029.USD","STRK","BK4566","GFS","IE00B5949003.HKD","LU2045819591.USD","LU1861217088.USD","AX","BK4573","IE0004445239.USD","LU2458330169.SGD","BK4512","BK4612","BK4529","BK4600","BK4588","LU2360107671.USD","IE00BMPRXN33.USD","LU1989764664.SGD"],"gpt_icon":0},{"id":"2520371084","title":"Clearside Biomedical’s Lead Clinical Program CLS-AX in Wet AMD  and Suprachoroidal Delivery Platform Highlighted at the  2025 Wet AMD & Diabetic Eye Disease Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2520371084","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520371084?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 19:05","pubTimestamp":1742468700,"startTime":"0","endTime":"0","summary":"- Post-Hoc Analyses Provide Comparative Data on Rescue Criteria and Intervention-Free Rates for Tyrosine Kinase Inhibitors (TKIs) in Wet AMD Development - - Unique Ability to Re-Dose CLS-AX vs Rescue ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/20/3046109/0/en/Clearside-Biomedical-s-Lead-Clinical-Program-CLS-AX-in-Wet-AMD-and-Suprachoroidal-Delivery-Platform-Highlighted-at-the-2025-Wet-AMD-Diabetic-Eye-Disease-Summit.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0198837287.USD","LU1951200564.SGD","BK4554","CLS","BK4145","BK4512","BK4605","LU0823421333.USD","LU1989764664.SGD","LU0889565833.HKD","LU1880398554.USD","LU0390134368.USD","BK4141","LU1951198990.SGD","LU0823434740.USD","IE00BMPRXR70.SGD","BK4575","IE00BMPRXN33.USD","LU0642271901.SGD","LU1316542783.SGD","LU1303367103.USD","GFS","LU0979878070.USD","LU2250418816.HKD","LU1861220207.SGD","LU1803068979.SGD","LU2054465674.USD","BK4529","LU0823434583.USD","LU1064131342.USD","SMMF","BK4195","BK4566","LU1923623000.USD","LU1242518857.USD","BK4534","LU1988902786.USD","CLSD","IE0009356076.USD","AX","LU0127658192.USD","IE00B5949003.HKD","BK4532","LU2360106780.USD","LU0081259029.USD","LU2125910500.SGD","LU2360107671.USD","LU1852331112.SGD","BK4588"],"gpt_icon":1},{"id":"2517486987","title":"Clearside Biomedical Inc  expected to post a loss of 10 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2517486987","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517486987?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 19:39","pubTimestamp":1741347555,"startTime":"0","endTime":"0","summary":"Clearside Biomedical Inc  expected to post a loss of10cents a share - Earnings Preview Clearside Biomedical Inc CLSD.OQ CLSD.O is expected to show a fall in quarterly revenue when it reports  results ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250307:nL5N3PQ0SO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLSD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.clearsidebio.com","stockEarnings":[{"period":"1week","weight":-0.0975},{"period":"1month","weight":-0.1172},{"period":"3month","weight":-0.158},{"period":"6month","weight":-0.3795},{"period":"1year","weight":-0.365},{"period":"ytd","weight":-0.1378}],"compareEarnings":[{"period":"1week","weight":-0.115},{"period":"1month","weight":-0.1379},{"period":"3month","weight":-0.1578},{"period":"6month","weight":-0.1383},{"period":"1year","weight":-0.0429},{"period":"ytd","weight":-0.1529}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.035821},{"month":2,"riseRate":0.444444,"avgChangeRate":-0.036687},{"month":3,"riseRate":0.555556,"avgChangeRate":0.062704},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.022334},{"month":5,"riseRate":0.25,"avgChangeRate":-0.080267},{"month":6,"riseRate":0.75,"avgChangeRate":0.163204},{"month":7,"riseRate":0.444444,"avgChangeRate":-0.038074},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.074112},{"month":9,"riseRate":0.444444,"avgChangeRate":0.150007},{"month":10,"riseRate":0.333333,"avgChangeRate":0.04158},{"month":11,"riseRate":0.555556,"avgChangeRate":-0.029261},{"month":12,"riseRate":0.333333,"avgChangeRate":0.048543}],"exchange":"NASDAQ","name":"Clearside Biomedical","nameEN":"Clearside Biomedical"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.2","shortVersion":"4.32.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Clearside Biomedical(CLSD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Clearside Biomedical(CLSD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Clearside Biomedical,CLSD,Clearside Biomedical股票,Clearside Biomedical股票老虎,Clearside Biomedical股票老虎国际,Clearside Biomedical行情,Clearside Biomedical股票行情,Clearside Biomedical股价,Clearside Biomedical股市,Clearside Biomedical股票价格,Clearside Biomedical股票交易,Clearside Biomedical股票购买,Clearside Biomedical股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Clearside Biomedical(CLSD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Clearside Biomedical(CLSD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}